Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 7 of 37, showing 5 Applications out of 183 total, starting on record 31, ending on 35

# Protocol No Study Title Investigator(s) & Site(s)

31.

ECCT/24/02/09   pionERA
    This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of   giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor   (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal   growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant   endocrine therapy.   
Principal Investigator(s)
1. Dr Sitna Ali
Site(s) in Kenya
University of Nairobi -Institute of Tropical and Infectious Diseases
 
View

32.

ECCT/23/10/08   VALUE Placebo Film Study
    Trial to Assess Acceptability and Safety of Two Placebo Prototype Vaginal Films (MATRIX-002)   
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
KEMRI-CCR PHRD Thika
 
View

33.

ECCT/13/08/06  
    Management of myocardial injury After NoncArdiac surgGEry (MANAGE) Trial   
Principal Investigator(s)
1. GERALD OCHIENG\' YONGA
2. LEONARD MZEE NGUNGA
Site(s) in Kenya
Aga Khan University Hospital, Nairobi
 
View

34.

ECCT/22/03/01   The \"NOVATION-1\" Trial
    A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Safety and Efficacy of Aerosolized Novaferon + SOC vs. Placebo + SOC in Hospitalized Adult Patients with Moderate to Severe COVID-19   
Principal Investigator(s)
1. Dr John Kinuthia
Site(s) in Kenya
1. Center for Research in Therapeutic Sciences(CREATES) (Nairobi City county)
2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)
3. KEMRI Kericho (Kericho county)
4. KEMRI Siaya (Kisumu county)
5. Kenyatta National Hospital (Nairobi City county)
 
View

35.

ECCT/19/03/02   PREVENT TD
    A Randomized, Placebo-Controlled, Double-Blind, Clinical Trial Evaluating Two Dose Regimens of Rifaximin (550 mg daily or 550 mg twice daily) for Chemoprophylaxis Against Travellers’ Diarrhoea (TD) Among Active Duty Deployed U.S. and British Military Personnel (PREVENT TD)   
Principal Investigator(s)
1. Flynn Alexander
Site(s) in Kenya
Nyati Barracks, British Army Training Unit, Kenya
 
View